PE64598A1 - Derivados del indazol sustituidos y compuestos relacionados - Google Patents
Derivados del indazol sustituidos y compuestos relacionadosInfo
- Publication number
- PE64598A1 PE64598A1 PE1997000330A PE00033097A PE64598A1 PE 64598 A1 PE64598 A1 PE 64598A1 PE 1997000330 A PE1997000330 A PE 1997000330A PE 00033097 A PE00033097 A PE 00033097A PE 64598 A1 PE64598 A1 PE 64598A1
- Authority
- PE
- Peru
- Prior art keywords
- formula
- compounds
- preference
- related compounds
- double link
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical class C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 title 1
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 abstract 2
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 abstract 2
- 229940124639 Selective inhibitor Drugs 0.000 abstract 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- QUPDWYMUPZLYJZ-UHFFFAOYSA-N ethyl Chemical class C[CH2] QUPDWYMUPZLYJZ-UHFFFAOYSA-N 0.000 abstract 1
- CBOIHMRHGLHBPB-UHFFFAOYSA-N hydroxymethyl Chemical group O[CH2] CBOIHMRHGLHBPB-UHFFFAOYSA-N 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
- 102000003390 tumor necrosis factor Human genes 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/08—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing alicyclic rings
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Transplantation (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
SE REFIEREN A COMPUESTOS DE FORMULA (I) Y A COMPUESTOS INTERMEDIOS DE FORMULA (XV) Y (XIX), EN DONDE: R ES H, ALQUILO C1-C6 O (CH2)n(CICLOALQUILO C3-C7), ENTRE OTROS, EN DONDE: n ES 0; 1 o 2; SIENDO DE PREFERENCIA R UN CICLOHEXILO O CICLOPENTILO; R1 ES DE PREFERENCIA ETILO; R2 ES DE PREFERENCIA (Ia), EN DONDE LAS LINEAS DISCONTINUAS SON UN ENLACE SENCILLO O DOBLE, CON LA CONDICION DE QUE SI R5 ESTA AUSENTE CUANDO LA LINEA DISCONTINUA EN LA FORMULA (Ia) ES UN DOBLE ENLACE; R3 ES H O CN, ENTRE OTROS; R4 ES CARBOXI, CH2OH O CH2CONH2, ENTRE OTROS; R5 ES R9, OR9 O CH2OR9, ENTRE OTROS; O R4 Y R5 SE UNEN PARA FORMAR =O o =R8; R8 ES =NCN O =NCR9R10(ALQUENILO C2-C6), ENTRE OTROS; R9 Y R10 SON H O ALQUILO C1-C4 OPCIONALMENTE SUSTITUIDO HASTA CON 3 FLUOR. ESTOS COMPUESTOS ACTUAN COMO INHIBIDORES SELECTIVOS DE LA FOSFODIESTERASA (PDE) TIPO IV Y DE LA PRODUCCION DEL FACTOR DE NECROSIS TUMORAL, SIENDO UTIL EN EL TRATAMIENTO DEL ASMA, DE LA ARTRITIS REUMATOIDEA, ENTRE OTROS
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US1686196P | 1996-05-03 | 1996-05-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE64598A1 true PE64598A1 (es) | 1998-10-26 |
Family
ID=21779401
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE1997000330A PE64598A1 (es) | 1996-05-03 | 1997-04-30 | Derivados del indazol sustituidos y compuestos relacionados |
Country Status (41)
| Country | Link |
|---|---|
| US (2) | US6211222B1 (es) |
| EP (1) | EP0912521B1 (es) |
| JP (1) | JP3148254B2 (es) |
| KR (1) | KR100339935B1 (es) |
| CN (2) | CN1112359C (es) |
| AP (4) | AP1147A (es) |
| AR (1) | AR006906A1 (es) |
| AT (1) | ATE292626T1 (es) |
| AU (1) | AU725576B2 (es) |
| BG (1) | BG64211B1 (es) |
| BR (1) | BR9709051A (es) |
| CA (2) | CA2252982C (es) |
| CO (1) | CO4650038A1 (es) |
| CZ (1) | CZ292825B6 (es) |
| DE (1) | DE69732966T2 (es) |
| DZ (1) | DZ2217A1 (es) |
| EA (1) | EA002272B1 (es) |
| ES (1) | ES2238079T3 (es) |
| GT (1) | GT199700043A (es) |
| HN (1) | HN1997000046A (es) |
| HR (1) | HRP970227B1 (es) |
| HU (1) | HUP9902459A3 (es) |
| ID (1) | ID16856A (es) |
| IL (2) | IL126547A (es) |
| IS (1) | IS4871A (es) |
| MA (1) | MA24158A1 (es) |
| MY (1) | MY132499A (es) |
| NO (1) | NO312959B1 (es) |
| NZ (1) | NZ332240A (es) |
| OA (1) | OA10904A (es) |
| PE (1) | PE64598A1 (es) |
| PL (1) | PL329836A1 (es) |
| SK (1) | SK148298A3 (es) |
| TN (1) | TNSN97070A1 (es) |
| TR (1) | TR199802202T2 (es) |
| TW (1) | TW449585B (es) |
| UA (1) | UA65536C2 (es) |
| UY (1) | UY24532A1 (es) |
| WO (1) | WO1997042174A1 (es) |
| YU (1) | YU16397A (es) |
| ZA (1) | ZA973804B (es) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6005118A (en) * | 1996-05-03 | 1999-12-21 | Caron; Stephane | Methods of preparing 4-cyano-4 (substituted indazole) cyclohexane-carboxylic acids useful as PDE4 inhibitors |
| AP1147A (en) * | 1996-05-03 | 2003-02-25 | Pfizer | Substituted indazole derivatives and related compounds. |
| WO1997048697A1 (en) | 1996-06-19 | 1997-12-24 | Rhone-Poulenc Rorer Limited | Substituted azabicylic compounds and their use as inhibitors of the production of tnf and cyclic amp phosphodiesterase |
| WO1998050367A1 (en) * | 1997-05-08 | 1998-11-12 | Pfizer Products Inc. | Processes and intermediates for preparing substituted indazole derivatives |
| SK6252000A3 (en) * | 1997-11-04 | 2001-11-06 | Pfizer Prod Inc | Indazole bioisostere replacement of catechol in therapeutically active compounds |
| NZ503995A (en) * | 1997-11-04 | 2003-02-28 | Pfizer Prod Inc | Indazole compounds, and pharmaceutical compositions and uses thereof, based on indazole bioisostere replacement of catechol in PDE4 inhibitors |
| IL126745A (en) * | 1997-11-04 | 2003-09-17 | Pfizer Prod Inc | Methods of preparing 4-cyano-4- (substituted indazole) cyclohexanecarboxylic acids useful as pde4 inhibitors |
| IL132407A0 (en) * | 1998-10-21 | 2001-03-19 | Pfizer Prod Inc | Method for treating congestive heart failure |
| JP2000198734A (ja) * | 1998-12-30 | 2000-07-18 | Pfizer Inc | 胃運動性減弱および関連疾患の治療のための運動性増強薬 |
| US6303782B1 (en) * | 1999-04-20 | 2001-10-16 | Pfizer Inc | Process for preparing benzylnitriles |
| US6362213B1 (en) | 1999-12-23 | 2002-03-26 | Icos Corporation | Cyclic AMP-specific phosphodiesterase inhibitors |
| PT1244649E (pt) * | 1999-12-23 | 2005-06-30 | Icos Corp | Inibidores de fosfodiesterase especificos de mfa ciclica |
| US7211594B2 (en) * | 2000-07-31 | 2007-05-01 | Signal Pharmaceuticals, Llc | Indazole compounds and compositions thereof as JNK inhibitors and for the treatment of diseases associated therewith |
| US6897231B2 (en) * | 2000-07-31 | 2005-05-24 | Signal Pharmaceuticals, Inc. | Indazole derivatives as JNK inhibitors and compositions and methods related thereto |
| US6953774B2 (en) | 2000-08-11 | 2005-10-11 | Applied Research Systems Ars Holding N.V. | Methods of inducing ovulation |
| CA2469939C (en) | 2001-12-14 | 2012-06-19 | Applied Research Systems Ars Holding N.V. | Method of inducing ovulation using a non-polypeptide camp level modulator |
| US20040034084A1 (en) * | 2002-05-24 | 2004-02-19 | Celgene Corporation | Methods for using JNK inhibitors for treating or preventing disease-related wasting |
| US7196082B2 (en) * | 2002-11-08 | 2007-03-27 | Merck & Co. Inc. | Ophthalmic compositions for treating ocular hypertension |
| US20050019366A1 (en) * | 2002-12-31 | 2005-01-27 | Zeldis Jerome B. | Drug-coated stents and methods of use therefor |
| DE10318610A1 (de) | 2003-04-24 | 2004-11-11 | Elbion Ag | 7-Azaindole und deren Verwendung als Therapeutika |
| US7601847B2 (en) | 2004-10-26 | 2009-10-13 | Wyeth | Preparation and purification of 4-(indazol-3-yl)phenols |
| US20070004777A1 (en) * | 2005-03-23 | 2007-01-04 | Bhagwat Shripad S | Methods for treating or preventing acute myelogenous leukemia |
| CA2620333A1 (en) | 2005-08-26 | 2007-03-01 | Braincells, Inc. | Neurogenesis by muscarinic receptor modulation |
| EP2258357A3 (en) | 2005-08-26 | 2011-04-06 | Braincells, Inc. | Neurogenesis with acetylcholinesterase inhibitor |
| JP2009512711A (ja) | 2005-10-21 | 2009-03-26 | ブレインセルス，インコーポレイティド | Ｐｄｅ阻害による神経新生の調節 |
| US20070112017A1 (en) | 2005-10-31 | 2007-05-17 | Braincells, Inc. | Gaba receptor mediated modulation of neurogenesis |
| US20100216734A1 (en) | 2006-03-08 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
| BRPI0710636A2 (pt) * | 2006-04-21 | 2011-08-23 | Centocor Inc | antagonistas de cxcl 31 e o uso dos mesmos para o tratamento de doenças inflamatórias |
| EP2382975A3 (en) | 2006-05-09 | 2012-02-29 | Braincells, Inc. | Neurogenesis by modulating angiotensin |
| US20100184806A1 (en) | 2006-09-19 | 2010-07-22 | Braincells, Inc. | Modulation of neurogenesis by ppar agents |
| WO2010099217A1 (en) | 2009-02-25 | 2010-09-02 | Braincells, Inc. | Modulation of neurogenesis using d-cycloserine combinations |
| EP2804603A1 (en) | 2012-01-10 | 2014-11-26 | President and Fellows of Harvard College | Beta-cell replication promoting compounds and methods of their use |
| WO2019090272A1 (en) | 2017-11-06 | 2019-05-09 | Flx Bio, Inc. | Chemokine receptor modulators for treatment of epstein barr virus positive cancer |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3994890A (en) * | 1974-01-31 | 1976-11-30 | Chugai Seiyaku Kabushiki Kaisha | 1-Aminoalkyl, 3-phenyl indazoles |
| JPS5654437A (en) * | 1979-10-09 | 1981-05-14 | Konishiroku Photo Ind Co Ltd | Direct positive image forming method |
| GB8707051D0 (en) * | 1986-04-15 | 1987-04-29 | Ici America Inc | Heterocyclic carboxamides |
| JP2525286B2 (ja) * | 1990-11-26 | 1996-08-14 | 日本原子力研究所 | 超耐熱性炭化ケイ素繊維の製造方法 |
| TW223004B (es) * | 1991-11-25 | 1994-05-01 | Sumitomo Chemical Co | |
| DE69328964T2 (de) * | 1992-03-09 | 2000-11-09 | Zeneca Ltd., London | Arylindazoline und ihre anwendung als herbizide |
| US5444038A (en) * | 1992-03-09 | 1995-08-22 | Zeneca Limited | Arylindazoles and their use as herbicides |
| MX9301943A (es) * | 1992-04-02 | 1994-08-31 | Smithkline Beecham Corp | Compuestos. |
| US5554620A (en) * | 1993-09-14 | 1996-09-10 | Sterling Winthrop Inc. | Substituted 6,11-ethano-6,11-dihydrobenzo[b] quinolizinium salts and compositions and methods of use thereof |
| US5440038A (en) * | 1993-12-07 | 1995-08-08 | Miles Inc. | Process for the purification of substituted 4-amino-1,2,4-triazine-5-ones |
| JPH09511758A (ja) * | 1994-10-20 | 1997-11-25 | フアイザー・インコーポレイテツド | 二環式テトラヒドロピラゾロピリジンおよび医薬としてのその使用 |
| CA2203181C (en) * | 1994-10-21 | 2001-08-07 | Robert L. Heimann | Corrosion preventing buffer system for metal products |
| AP1147A (en) * | 1996-05-03 | 2003-02-25 | Pfizer | Substituted indazole derivatives and related compounds. |
| WO1998050367A1 (en) * | 1997-05-08 | 1998-11-12 | Pfizer Products Inc. | Processes and intermediates for preparing substituted indazole derivatives |
-
1996
- 1996-05-03 AP APAP/P/2001/002294A patent/AP1147A/en active
- 1996-05-03 AP AP2001002304A patent/AP2001002304A0/xx unknown
-
1997
- 1997-01-04 UA UA98105434A patent/UA65536C2/uk unknown
- 1997-04-01 EP EP97907247A patent/EP0912521B1/en not_active Expired - Lifetime
- 1997-04-01 KR KR1019980708867A patent/KR100339935B1/ko not_active Expired - Fee Related
- 1997-04-01 CN CN97194356A patent/CN1112359C/zh not_active Expired - Fee Related
- 1997-04-01 AU AU19373/97A patent/AU725576B2/en not_active Ceased
- 1997-04-01 DE DE69732966T patent/DE69732966T2/de not_active Expired - Fee Related
- 1997-04-01 TW TW086104176A patent/TW449585B/zh active
- 1997-04-01 ES ES97907247T patent/ES2238079T3/es not_active Expired - Lifetime
- 1997-04-01 EA EA199800882A patent/EA002272B1/ru not_active IP Right Cessation
- 1997-04-01 NZ NZ332240A patent/NZ332240A/xx unknown
- 1997-04-01 TR TR1998/02202T patent/TR199802202T2/xx unknown
- 1997-04-01 PL PL97329836A patent/PL329836A1/xx unknown
- 1997-04-01 IL IL12654797A patent/IL126547A/xx not_active IP Right Cessation
- 1997-04-01 HU HU9902459A patent/HUP9902459A3/hu unknown
- 1997-04-01 AT AT97907247T patent/ATE292626T1/de not_active IP Right Cessation
- 1997-04-01 CA CA002252982A patent/CA2252982C/en not_active Expired - Fee Related
- 1997-04-01 BR BR9709051A patent/BR9709051A/pt active Search and Examination
- 1997-04-01 CA CA002389918A patent/CA2389918A1/en not_active Abandoned
- 1997-04-01 JP JP53967097A patent/JP3148254B2/ja not_active Expired - Fee Related
- 1997-04-01 CZ CZ19983492A patent/CZ292825B6/cs not_active IP Right Cessation
- 1997-04-01 SK SK1482-98A patent/SK148298A3/sk unknown
- 1997-04-01 AP APAP/P/2001/002304A patent/AP0102304A0/en unknown
- 1997-04-01 IL IL15208397A patent/IL152083A0/xx unknown
- 1997-04-01 WO PCT/IB1997/000323 patent/WO1997042174A1/en not_active Ceased
- 1997-04-04 HN HN1997000046A patent/HN1997000046A/es unknown
- 1997-04-10 GT GT199700043A patent/GT199700043A/es unknown
- 1997-04-28 UY UY24532A patent/UY24532A1/es not_active IP Right Cessation
- 1997-04-29 AR ARP970101769A patent/AR006906A1/es not_active Application Discontinuation
- 1997-04-29 YU YU16397A patent/YU16397A/sh unknown
- 1997-04-30 TN TNTNSN97070A patent/TNSN97070A1/fr unknown
- 1997-04-30 MA MA24577A patent/MA24158A1/fr unknown
- 1997-04-30 AP APAP/P/1997/000975A patent/AP1146A/en active
- 1997-04-30 DZ DZ970064A patent/DZ2217A1/fr active
- 1997-04-30 PE PE1997000330A patent/PE64598A1/es not_active Application Discontinuation
- 1997-05-02 ID IDP971466A patent/ID16856A/id unknown
- 1997-05-02 HR HR970227A patent/HRP970227B1/xx not_active IP Right Cessation
- 1997-05-02 MY MYPI97001923A patent/MY132499A/en unknown
- 1997-05-02 ZA ZA973804A patent/ZA973804B/xx unknown
- 1997-05-05 CO CO97023872A patent/CO4650038A1/es unknown
- 1997-11-04 US US08/963,904 patent/US6211222B1/en not_active Expired - Fee Related
-
1998
- 1998-10-16 IS IS4871A patent/IS4871A/is unknown
- 1998-10-23 OA OA9800201A patent/OA10904A/en unknown
- 1998-11-02 NO NO19985095A patent/NO312959B1/no not_active IP Right Cessation
- 1998-11-23 BG BG102946A patent/BG64211B1/bg unknown
-
1999
- 1999-09-27 US US09/406,220 patent/US6127398A/en not_active Expired - Fee Related
-
2002
- 2002-11-08 CN CN02149950A patent/CN1422849A/zh active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE64598A1 (es) | Derivados del indazol sustituidos y compuestos relacionados | |
| HN2003000100A (es) | Compuestos utiles en terapia | |
| PE20060857A1 (es) | Derivados de piridinilo y pirimidinilo sustituidos como moduladores del metabolismo y para tratar trastornos metabolicos | |
| AR039489A1 (es) | Derivados de tetrahidropiranil ciclopentil tetrahidropiridopiridina, moduladores de actividad de receptores de citoquinas | |
| CY1107196T1 (el) | Υποκατεστημενα παραγωγα 2,4-διϋδρο-πυρρολο (3,4-β) -κινολιν-9-ονης χρησιμα ως αναστολεις της φωσφοδιεστερασης | |
| ES2051796T3 (es) | Procedimiento para preparar derivados de dihidrobenzopiran-2-carboxilatos alcoxi-sustituidos. | |
| HRP20050524B1 (hr) | Plinski plamenik s odvojenim napajanjem plamenskih vijenaca | |
| PE108099A1 (es) | Acidos 5-alquil-2-arilaminofenilaceticos y sus derivados | |
| AR039743A1 (es) | Fenilbenzamidas y su uso para el control de microoganismos indeseados | |
| UY28708A1 (es) | Heterociclos sustituídos y usos de los mismos | |
| ES2154683T3 (es) | Indoles sustituidos como inhibidores de fosfodiesterasa de tipo iv. | |
| PE20050131A1 (es) | Derivados de benzoimidazol como agentes antiproliferativos | |
| ES2173846T3 (es) | Compuestos de biciclocarbonil indol como agentes antiinflamatorios/analgesicos y como inhibidores de cox-2. | |
| CY1109300T1 (el) | Νεοι συντηγμενοι ετεροκυκλικοι δακτυλιοι και χρησεις αυτων | |
| CR8842A (es) | Derivados de pirido-pirimidina, su preparacion, su aplicacion en terapeutica | |
| PE20030208A1 (es) | Derivados de indirubina que contienen azufre, su preparacion y uso | |
| MXPA05010793A (es) | Beta-carbolinas utiles para tratar enfermedades inflamatorias. | |
| TR200400228T4 (tr) | Psöryazinin tedavisinde kullanılacak maddeler | |
| ATE505462T1 (de) | Neue biologischaktive molekü le | |
| PE20050483A1 (es) | Derivados de tetrazol de formula (i), sus composiciones farmaceuticas y procesos para producir composiciones farmaceuticas | |
| AR054551A1 (es) | Metodos para la neuroproteccion | |
| SV2005002092A (es) | " proceso de acoplamiento para la generacion de derivados reactivos de pirrol-2-carbonitrilo n-sustituidos con contenido de boro para producir biarilos " ref. am - 101481salvo. | |
| PE20081693A1 (es) | Derivados de cinolin-3-carboxamida como inhibidores de csf-1r | |
| SE0301963D0 (sv) | New compounds | |
| UY29070A1 (es) | Enantiómeros de heterocíclicos fusionados y sus usos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration | ||
| FD | Application declared void or lapsed |